Telmisartan, identified by its CAS number 144701-48-4, is a widely used pharmaceutical compound that belongs to the class of drugs known as angiotensin II receptor blockers (ARBs). It is primarily prescribed for the management of hypertension (high blood pressure) and for reducing cardiovascular risk in certain patient populations. Over the years, Telmisartan has gained significant clinical relevance due to its effectiveness, safety profile, and additional benefits beyond blood pressure control.


Chemical and Physical Properties

  • Chemical Name: 4'-[(1,4'-dimethyl-2-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
  • Molecular Formula: C₃₃H₃₀N₄O₂
  • Molecular Weight: 514.6 g/mol
  • Appearance: White to slightly yellowish crystalline powder
  • Solubility: Practically insoluble in water, freely soluble in strong base and DMSO

Telmisartan is a non-peptide molecule, structurally engineered to effectively block angiotensin II type 1 (AT1) receptors, thereby preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II.


Mechanism of Action

Telmisartan works by selectively antagonizing the AT1 receptor, which is primarily responsible for the physiological effects of angiotensin II, such as vasoconstriction, sodium retention, and aldosterone release. By inhibiting this receptor, Telmisartan promotes vasodilation, reduces blood volume, and ultimately lowers blood pressure.

Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs like Telmisartan do not inhibit the breakdown of bradykinin, thus minimizing the risk of side effects such as persistent dry cough or angioedema.



Therapeutic Applications

1. Hypertension

Telmisartan is primarily indicated for the treatment of essential hypertension. By lowering systemic blood pressure, it reduces the risk of stroke, heart attack, and other cardiovascular events. 

2. Cardiovascular Risk Reduction

Clinical studies have shown that Telmisartan can significantly reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients who are unable to take ACE inhibitors. This is particularly beneficial for individuals with a history of cardiovascular disease or type 2 diabetes with target organ damage.

3. Renal Protection in Diabetes

Telmisartan has been found to delay the progression of nephropathy in type 2 diabetic patients with hypertension. It helps in preserving kidney function by reducing glomerular pressure and proteinuria.

Pharmacokinetics

Telmisartan is well absorbed orally, although its absolute bioavailability is around 42%. This extended half-life contributes to more stable blood pressure control over a 24-hour period. The drug is highly bound to plasma proteins, and it is eliminated primarily via feces with minimal renal excretion.


Safety and Side Effects

Telmisartan is generally well-tolerated. The most common side effects reported include:

  • Dizziness
  • Fatigue
  • Sinusitis
  • Diarrhea

Serious side effects are rare but can include hyperkalemia, renal impairment, and hypotension, particularly in volume-depleted patients or those with renal artery stenosis.

It is contraindicated in pregnancy due to its potential to cause injury and even death to the developing fetus when administered during the second and third trimesters.


Drug Interactions

Like other ARBs, Telmisartan may interact with:

  • Potassium-sparing diuretics and supplements: Increasing the risk of hyperkalemia
  • NSAIDs: Potentially reducing antihypertensive efficacy and impairing renal function
  • Lithium: May increase serum lithium levels and risk of toxicity

Patients on multiple medications should be closely monitored to avoid harmful interactions.


Advantages Over Other ARBs

Telmisartan stands out among ARBs due to several unique features:

  • Longest half-life among commonly used ARBs, ensuring sustained 24-hour blood pressure control
  • Partial PPAR-γ agonist activity, which may provide metabolic benefits such as improved insulin sensitivity
  • Effective cardiovascular risk reduction, as demonstrated in multiple large-scale clinical trials

These attributes make Telmisartan a favorable choice for patients with comorbid conditions such as diabetes and metabolic syndrome.


Storage and Handling

Its solid-state form is stable under normal environmental conditions, but exposure to high humidity or direct sunlight may lead to degradation. Handling of the active pharmaceutical ingredient (API) should follow standard safety procedures to minimize dust inhalation or skin contact.


Conclusion

Telmisartan (CAS No. 144701-48-4) has established itself as a highly effective and well-tolerated ARB for the management of hypertension and reduction of cardiovascular risks. Its long duration of action, renal protective effects, and potential metabolic advantages make it a versatile therapeutic agent. With a strong foundation of clinical evidence and a favorable safety profile, Telmisartan continues to be a cornerstone in the pharmacological treatment of high blood pressure and related conditions.

URL: For more information, visit Verdant Pharma : CAS NO 144701-48-4 (TELMISARTAN)